Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plexus (PLXS) Cash & Equivalents (2016 - 2026)

Historic Cash & Equivalents for Plexus (PLXS) over the last 18 years, with Q1 2026 value amounting to $248.8 million.

  • Plexus' Cash & Equivalents fell 2154.62% to $248.8 million in Q1 2026 from the same period last year, while for Jan 2026 it was $248.8 million, marking a year-over-year decrease of 2154.62%. This contributed to the annual value of $306.5 million for FY2025, which is 1119.79% down from last year.
  • According to the latest figures from Q1 2026, Plexus' Cash & Equivalents is $248.8 million, which was down 2154.62% from $306.5 million recorded in Q3 2025.
  • Plexus' 5-year Cash & Equivalents high stood at $345.1 million for Q3 2024, and its period low was $217.1 million during Q1 2022.
  • For the 5-year period, Plexus' Cash & Equivalents averaged around $272.7 million, with its median value being $269.7 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 3914.99% in 2022, then surged by 3671.79% in 2024.
  • Plexus' Cash & Equivalents (Quarter) stood at $247.9 million in 2022, then fell by 6.41% to $232.0 million in 2023, then soared by 36.72% to $317.2 million in 2024, then decreased by 3.37% to $306.5 million in 2025, then decreased by 18.81% to $248.8 million in 2026.
  • Its Cash & Equivalents stands at $248.8 million for Q1 2026, versus $306.5 million for Q3 2025 and $237.6 million for Q2 2025.